Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience.
Parisi A, Palluzzi E, Cortellini A, Sidoni T, Cocciolone V, Lanfiuti Baldi P, Porzio G, Ficorella C, Cannita K. Parisi A, et al. Among authors: porzio g. Clin Transl Oncol. 2020 Jan;22(1):158-162. doi: 10.1007/s12094-019-02122-x. Epub 2019 Apr 30. Clin Transl Oncol. 2020. PMID: 31041717 Clinical Trial.
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M. Cortellini A, et al. Among authors: porzio g. Clin Transl Oncol. 2020 Jun;22(6):844-851. doi: 10.1007/s12094-019-02193-w. Epub 2019 Aug 7. Clin Transl Oncol. 2020. PMID: 31392645
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study.
Ficorella C, Morelli MF, Ricevuto E, Cannita K, Porzio G, Baldi PL, Cianci G, DI Rocco ZC, Natoli C, Tinari N, DE Galitiis F, Calista F, Marchetti P. Ficorella C, et al. Among authors: porzio g. Br J Cancer. 2004 Aug 16;91(4):618-20. doi: 10.1038/sj.bjc.6601971. Br J Cancer. 2004. PMID: 15292944 Free PMC article. Clinical Trial.
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Ficorella C, Ricevuto E, Morelli MF, Morese R, Cannita K, Cianci G, Porzio G, Di Rocco ZC, De Galitiis F, De Tursi M, Tinari N, Iacobelli S, Marchetti P. Ficorella C, et al. Among authors: porzio g. Oncol Rep. 2006 May;15(5):1345-50. doi: 10.3892/or.15.5.1345. Oncol Rep. 2006. PMID: 16596209 Clinical Trial.
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Morelli MF, Santomaggio A, Ricevuto E, Cannita K, De Galitiis F, Tudini M, Bruera G, Mancini M, Pelliccione M, Calista F, Guglielmi F, Martella F, Lanfiuti Baldi P, Porzio G, Russo A, Gebbia N, Iacobelli S, Marchetti P, Ficorella C. Morelli MF, et al. Among authors: porzio g. Oncol Rep. 2010 Jun;23(6):1635-40. doi: 10.3892/or_00000805. Oncol Rep. 2010. PMID: 20428819 Free article. Clinical Trial.
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Banna GL, Cortellini A, Cortinovis DL, Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, Grossi F, Pizzutilo P, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Marco R, Cantini L, Nigro O, D'Argento E, Buti S, Minuti G, Landi L, Guaitoli G, Lo Russo G, De Toma A, Donisi C, Friedlaender A, De Giglio A, Metro G, Porzio G, Ficorella C, Addeo A. Banna GL, et al. Among authors: porzio g. ESMO Open. 2021 Apr;6(2):100078. doi: 10.1016/j.esmoop.2021.100078. Epub 2021 Mar 16. ESMO Open. 2021. PMID: 33735802 Free PMC article.
Prognostic value of p53 molecular status in high-risk primary breast cancer.
Marchetti P, Cannita K, Ricevuto E, De Galitiis F, Di Rocco ZC, Tessitore A, Bisegna R, Porzio G, De Rubeis GP, Ventura T, Martinotti S, Ficorella C. Marchetti P, et al. Among authors: porzio g. Ann Oncol. 2003 May;14(5):704-8. doi: 10.1093/annonc/mdg197. Ann Oncol. 2003. PMID: 12702523 Free article.
201 results